Patents by Inventor Jörg MEDING

Jörg MEDING has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bispecific antibodies binding ALK-1 and BMPR-2
    Publication number: 20220185901
    Abstract: The present invention relates to bispecific antibodies binding human ALK-1 and human BMPR-2. Also provided are BsABs which are agonists of ALK-1/BMPR-2 signaling, and BsABs which do not trigger osteogenic signaling. Furthermore, the invention relates to pharmaceutical uses of the BsABs, in particular for the treatment of pulmonary hypertension. Also provided are methods to screen for BsABs for use in the therapy, e.g., of pulmonary hypertension.
    Type: Application
    Filed: February 25, 2022
    Publication date: June 16, 2022
    Inventors: Ernst WEBER, Joerg MEDING, Florian SOHLER, Julian Marius GLUECK
  • Substituted [1,2,4]triazolo[4,3-A]pyrazines as prolyl endopeptidase inhibitors
    Patent number: 11337973
    Abstract: The invention relates to prolyl endopeptidase (PREP) inhibitors of formula (I) which contain a condensed 2,4-dihydro-3H-1,2,4-triazol-3-one ring system, methods for producing same, the use thereof alone or in combinations for treating and/or preventing diseases, and the use thereof for producing drugs for treating and/or preventing diseases, in particular for treating and/or preventing inflammatory lung diseases (COPD).
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: May 24, 2022
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Nicole Biber, Damian Brockschnieder, Florian Kölling, Jörg Meding, Hideki Miyatake Ondozabal, Thomas Neubauer, Martina Schäfer, Dmitry Zubov, Carsten Terjung
  • Bispecific antibodies binding ALK-1 and BMPR-2
    Patent number: 11292846
    Abstract: Bispecific antibodies binding ALK-1 and BMPR-2 The present invention relates to bispecific antibodies binding human ALK-1 and human BMPR-2. Also provided are BsABs which are agonists of ALK-1/BMPR-2 signaling, and BsABs which do not trigger osteogenic signaling. Furthermore, the invention relates to pharmaceutical uses of the BsABs, in particular for the treatment of pulmonary hypertension. Also provided are methods to screen for BsABs for use in the therapy, e.g. of pulmonary hypertension.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: April 5, 2022
    Assignee: Bayer Aktiengesellschaft
    Inventors: Ernst Weber, Joerg Meding, Florian Sohler, Julian Marius Glueck
  • SUBSTITUTED 2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONES AND USE OF SAME
    Publication number: 20200375986
    Abstract: The invention relates to prolyl endopeptidase (PREP) inhibitors which contain a condensed 2,4-dihydro-3H-1,2,4-triazol-3-one ring system, methods for producing same, the use thereof alone or in combinations for treating and/or preventing diseases, and the use thereof for producing drugs for treating and/or preventing diseases, in particular for treating and/or preventing inflammatory lung diseases (COPD).
    Type: Application
    Filed: October 31, 2018
    Publication date: December 3, 2020
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Nicole BIBER, Damian BROCKSCHNIEDER, Florian KÖLLING, Jörg MEDING, Hideki MIYATAKE ONDOZABAL, Thomas NEUBAUER, Martina SCHÄFER, Dmitry ZUBOV, Carsten TERJUNG
  • Bispecific antibodies binding ALK-1 and BMPR-2
    Publication number: 20200332013
    Abstract: Bispecific antibodies binding ALK-1 and BMPR-2 The present invention relates to bispecific antibodies binding human ALK-1 and human BMPR-2. Also provided are BsABs which are agonists of ALK-1/BMPR-2 signaling, and BsABs which do not trigger osteogenic signaling. Furthermore, the invention relates to pharmaceutical uses of the BsABs, in particular for the treatment of pulmonary hypertension. Also provided are methods to screen for BsABs for use in the therapy, e.g. of pulmonary hypertension.
    Type: Application
    Filed: October 25, 2018
    Publication date: October 22, 2020
    Inventors: Ernst Weber, Joerg Meding, Florian Sohler, Julian Marius Glueck
  • Substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-A]pyridine-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-C][1,2,4]triazol-3-ones, and use thereof
    Patent number: 10722501
    Abstract: The present application relates to novel substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-c][1,2,4]triazol-3-ones of formula (I), to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of lung inflammation disorders.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: July 28, 2020
    Assignees: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Nicole Biber, Damian Brockschnieder, Kersten Matthias Gericke, Florian Kölling, Klemens Lustig, Jörg Meding, Heinrich Meier, Thomas Neubauer, Martina Schäfer, Andreas Timmermann, Dmitry Zubov, Carsten Terjung, Niels Lindner, Volker Badock, Dieter Moosmayer, Hideki Miyatake Ondozabal, Stephen Moore, Alexander Schulz
  • SUBSTITUTED 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRIDINE-3(2H)-ONES AND 2,5,6,7-TETRAHYDRO-3H-PYRROLO[2,1-C][1,2,4]TRIAZOL-3-ONES, AND USE THEREOF
    Publication number: 20190160048
    Abstract: The present application relates to novel substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-c][1,2,4]triazol-3-ones, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of lung inflammation disorders.
    Type: Application
    Filed: May 8, 2017
    Publication date: May 30, 2019
    Applicants: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Nicole BIBER, Damian BROCKSCHNIEDER, Kersten Matthias GERICKE, Florian KÖLLING, Klemens LUSTIG, Jörg MEDING, Heinrich MEIER, Thomas NEUBAUER, Martina SCHÄFER, Andreas TIMMERMANN, Dmitry ZUBOV, Carsten TERJUNG, Niels LINDNER, Volker BADOCK, Dieter MOOSMAYER, Hideki MIYATAKE ONDOZABAL, Steven MOORE, Alexander SCHULZ
  • Perfluoroalkyl-Containing Complexes, Process For Their Production As Well As Their Use
    Publication number: 20090297454
    Abstract: The invention relates to the subjects that are characterized in the claims, namely perfluoroalkyl-containing metal complexes with nitrogen-containing radicals of general formula I, process for their production and their use in NMR and x-ray diagnosis, radiodiagnosis, and radiotherapy, as well as in MRT lymphography and in blood-pool imaging.
    Type: Application
    Filed: May 20, 2009
    Publication date: December 3, 2009
    Inventors: Heiko SCHIRMER, Hanns-Joachim Weinmann, Johannes Platzek, Ludwig Zorn, Bernd Misselwitz, Joerg Meding, Heribert Schmitt-Willich, Thomas Brumby
  • Perfluoroalkyl-containing complexes, process for their production as well as their use
    Patent number: 7618957
    Abstract: The invention relates to the subjects that are characterized in the claims, namely perfluoroalkyl-containing metal complexes with nitrogen-containing radicals of general formula I, process for their production and their use in NMR and x-ray diagnosis, radiodiagnosis, and radiotherapy, as well as in MRT lymphography and in blood-pool imaging.
    Type: Grant
    Filed: July 17, 2006
    Date of Patent: November 17, 2009
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Heiko Schirmer, Hanns-Joachim Weinmann, Johannes Platzek, Ludwig Zorn, Bernd Misselwitz, Joerg Meding, Heribert Schmitt-Willich, Thomas Brumby
  • Use of perfluoroalkyl-containing metal complexes as contrast media for diagnosis of Alzheimer's disease
    Publication number: 20070269384
    Abstract: The invention relates to the use of metal complexes that contain at least one perfluorinated alkyl radical and at least one chelating agent radical and at least one metal ion equivalent of the atomic numbers 21-29, 31-33, 37-39, 42-44, 49 or 57-83, as well as salts thereof for the production of a diagnostic agent for visualizing amyloid-containing plaques.
    Type: Application
    Filed: May 8, 2007
    Publication date: November 22, 2007
    Inventors: Bernd Misselwitz, Hanns-Joachim Weinmann, Joerg Meding
  • Perfluoroalkyl-containing complexes, process for their production as well as their use
    Publication number: 20070189969
    Abstract: The invention relates to the subjects that are characterized in the claims, namely perfluoroalkyl-containing metal complexes with nitrogen-containing radicals of general formula I, process for their production and their use in NMR and x-ray diagnosis, radiodiagnosis, and radiotherapy, as well as in MRT lymphography and in blood-pool imaging.
    Type: Application
    Filed: July 17, 2006
    Publication date: August 16, 2007
    Inventors: Heiko Schirmer, Hanns-Joachim Weinmann, Johannes Platzek, Ludwig Zorn, Bernd Misselwitz, Joerg Meding, Heribert Schmitt-Willich, Thomas Brumby
  • Perfluoroalkyl-containing complexes, process for their production as well as their use
    Publication number: 20070020183
    Abstract: The invention relates to the subjects that are characterized in the claims, namely perfluoroalkyl-containing metal complexes with an N-alkyl group of general formula 1, process for their production and their use in NMR and x-ray diagnosis, radiodiagnosis, and radiotherapy, as well as in MRT lymphography.
    Type: Application
    Filed: July 14, 2006
    Publication date: January 25, 2007
    Inventors: Heiko Schirmer, Hanns-Joachim Weinmann, Johannes Platzek, Ludwig Zorn, Bernd Misselwitz, Joerg Meding, Heribert Schmitt-Willich, Thomas Brumby